News & Highlights

Sander Meijer appointed professor of Pharmaceutical plasma proteins 

On 1 December 2016, Utrecht University appointed Sanquin researcher Dr Sander (AB) Meijer as professor of Pharmaceutical plasma proteins at the Faculty of Science.
Professor Meijer is head of the Laboratory of Proteomics and research manager of the Research Facilities of Sanquin. This department manages all the techniques in imaging and microscopy, next-generation DNA sequencing, proteomics, bioinformatics and animal models. There is a longstanding collaboration between Sanquin and Utrecht University.
 Sander Meijer
Prof Meijers’ research interest focuses on the biochemistry and clearing mechanisms of coagulation factors, in particular factor VIII and factor IX. His aim is to develop new therapeutics for the treatment of patients with haemophilia. In addition, prof Meijer develops innovative proteomics applications in his research on rare disorders of platelets. The chair Pharmaceuticals Plasma proteins exists since 1999, held by prof Koen Mertens, who will retire next year. With the appointment of prof Meijers, the continuity of education of pharmacy students and pharmacists in the field of plasma proteins is ensured.
December 2016


Website Innovative Training Network PROFILE live

PROFILE is an Innovative Training Network supported by the European Commission in its Horizon 2020 Marie Skłodowska-Curie program.

PROFILE focuses on the development of new diagnostic options for patients with acquired Thrombotic Thrombocytopenic Purpura (TTP). Within the consortium PROFILE, Sanquin works closely with international academic partners and industry to gain a better understanding of the factors that play a role in the onset and relapse of TTP.

   PROFILE logo
By understanding disease pathology, using new types of biomarkers and predicting risk for relapse; the outcome of this project will be crucial for better - personalized - treatment of patients. The unique research approach and the specialized translational training program offers opportunities for three PhD students who will spend part of their time at laboratories of academic partners as well as industry.

More information:

Maartje van den Biggelaar receives LSBR fellowship

In November 2015 Maartje van den Biggelaar received a fellowship from the Landsteiner Foundation for Blood Transfusion Research (LSBR). Every year one LSBR fellowship is awarded to a young excellent scientist working on blood, blood products or blood (related) disease. The fellowship of Maartje will allow her to study the interaction of hemostatic proteins with the vasculature focusing on dissection of coagulation-induced signaling networks using recently developed phosphoproteomic approaches. It is expected that through this unbiased approach novel targets for therapeutic intervention in bleeding and inflammatory disorders will be identified.     Maartje van den Biggelaar

Last edited on: 27 June 2017